company background image
TARS

Tarsus Pharmaceuticals NasdaqGS:TARS Stock Report

Last Price

US$18.50

Market Cap

US$493.2m

7D

8.2%

1Y

-28.8%

Updated

12 Aug, 2022

Data

Company Financials +
TARS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

TARS Stock Overview

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.

Tarsus Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tarsus Pharmaceuticals
Historical stock prices
Current Share PriceUS$18.50
52 Week HighUS$31.00
52 Week LowUS$10.80
Beta0
1 Month Change23.50%
3 Month Change40.90%
1 Year Change-28.79%
3 Year Changen/a
5 Year Changen/a
Change since IPO-10.11%

Recent News & Updates

May 13
Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues

Need To Know: Analysts Are Much More Bullish On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Revenues

Shareholders in Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) may be thrilled to learn that the analysts have just...

Shareholder Returns

TARSUS PharmaceuticalsUS Market
7D8.2%1.1%3.2%
1Y-28.8%1.3%-10.1%

Return vs Industry: TARS underperformed the US Pharmaceuticals industry which returned 0.7% over the past year.

Return vs Market: TARS underperformed the US Market which returned -11.7% over the past year.

Price Volatility

Is TARS's price volatile compared to industry and market?
TARS volatility
TARS Average Weekly Movement6.8%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: TARS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: TARS's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201646Bobby Azamianhttps://www.tarsusrx.com

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.

Tarsus Pharmaceuticals, Inc. Fundamentals Summary

How do Tarsus Pharmaceuticals's earnings and revenue compare to its market cap?
TARS fundamental statistics
Market CapUS$493.18m
Earnings (TTM)-US$56.40m
Revenue (TTM)US$17.39m

28.4x

P/S Ratio

-8.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TARS income statement (TTM)
RevenueUS$17.39m
Cost of RevenueUS$40.53m
Gross Profit-US$23.13m
Other ExpensesUS$33.26m
Earnings-US$56.40m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.12
Gross Margin-132.99%
Net Profit Margin-324.23%
Debt/Equity Ratio8.7%

How did TARS perform over the long term?

See historical performance and comparison